• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Metastatic Breast Cancer - Pipeline Review, H2 2012 Product Image

Metastatic Breast Cancer - Pipeline Review, H2 2012

  • Published: December 2012
  • 21 pages
  • Global Markets Direct

Metastatic Breast Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Metastatic Breast Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer. Metastatic Breast Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Breast Cancer.
- A review of the Metastatic Breast Cancer products under development READ MORE >

2
List of Tables 3
List of Figures 3
Introduction 4
REPORT COVERAGE 4
Metastatic Breast Cancer Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Metastatic Breast Cancer 6
Metastatic Breast Cancer Therapeutics under Development by Companies 8
Mid Clinical Stage Products 9
Comparative Analysis 9
Early Clinical Stage Products 10
Comparative Analysis 10
Discovery and Pre-Clinical Stage Products 11
Comparative Analysis 11
Metastatic Breast Cancer Therapeutics – Products under Development by Companies 12
Companies Involved in Metastatic Breast Cancer Therapeutics Development 13
Abbott Laboratories 13
Mesoblast Ltd 14
Yuhan Corporation 15
KOLON LIFE SCIENCE INC. 16
TissueGene, Inc. 17
Stem Cell Assurance, Inc. 18
Metastatic Breast Cancer – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21

List of Tables
Number of Products Under Development for Metastatic Breast Cancer, H2 2012 6
Products under Development for Metastatic Breast Cancer – Comparative Analysis, H2 2012 7
Number of Products under Development by Companies, H2 2012 8
Comparative Analysis by Mid Clinical Stage Development, H2 2012 9
Comparative Analysis by Early Clinical Stage Development, H2 2012 10
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Abbott Laboratories, H2 2012 13
Mesoblast Ltd, H2 2012 14
Yuhan Corporation, H2 2012 15
KOLON LIFE SCIENCE INC., H2 2012 16
TissueGene, Inc., H2 2012 17
Stem Cell Assurance, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19

List of Figures
Number of Products under Development for Metastatic Breast Cancer, H2 2012 6
Products under Development for Metastatic Breast Cancer – Comparative Analysis, H2 2012 7
Products under Development by Companies, H2 2012 8
Mid Clinical Stage Products, H2 2012 9
Early Clinical Stage Products, H2 2012 10
Discovery and Pre-Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 19

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos